KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Receivables - Other: 2009-2019

Historic Receivables - Other for Regeneron Pharmaceuticals (REGN) over the last 11 years, with Dec 2019 value amounting to $260.6 million.

  • Regeneron Pharmaceuticals' Receivables - Other rose 33.41% to $460.8 million in Q3 2020 from the same period last year, while for Sep 2020 it was $460.8 million, marking a year-over-year increase of 33.41%. This contributed to the annual value of $260.6 million for FY2019, which is 15.11% up from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its Receivables - Other stood at $260.6 million for FY2019, which was up 15.11% from $226.4 million recorded in FY2018.
  • In the past 5 years, Regeneron Pharmaceuticals' Receivables - Other ranged from a high of $260.6 million in FY2019 and a low of $93.0 million during FY2016.
  • Its 3-year average for Receivables - Other is $226.9 million, with a median of $226.4 million in 2018.
  • Per our database at Business Quant, Regeneron Pharmaceuticals' Receivables - Other tumbled by 39.28% in 2016 and then surged by 108.30% in 2017.
  • Regeneron Pharmaceuticals' Receivables - Other (Yearly) stood at $153.2 million in 2015, then slumped by 39.28% to $93.0 million in 2016, then skyrocketed by 108.30% to $193.7 million in 2017, then climbed by 16.88% to $226.4 million in 2018, then increased by 15.11% to $260.6 million in 2019.